Atrial FibrillationNCT07565337
The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
An observational study of Atrial Fibrillation and Biomarker, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation, Biomarker
- How many people
- 0 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Jan 2026to 31 Dec 2028
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study is a follow-up to the prospective generational study (AFTTER: Atrial Fibrillation Trial To Eliminate Risk-factors; NCT05718336) that enrolled patients from 2020 to 2023. After consenting to participate in this study, patients underwent a series of questionnaires, blood tests, and special examinations (see the figure below). The caregiver (the arrhythmia treatment team at National Taiwan University Hospital) formulated a treatment plan based on the examination results. After approximately two years (at least one year) of treatment, a post-test was conducted to conclude the study (a total of 343 patients were enrolled in this study, of which 266 participants completed the pre- and post-treatment tests and blood tests).
Who may be able to join
- -Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)
Who cannot join
- -Subjects without complete pre- and post-treatment testing
Trial locations and contacts
1 site in 1 country.
About this study
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
Read the detailed description
With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring.
Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.
- Conditions
- Atrial Fibrillation, Biomarker
- Keywords
- biomarker, atrial fibrillation, AF burden, inflammation, fibrosis, heart failure
- Medical subject headings
- Atrial Fibrillation, Inflammation, Fibrosis, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| afib | From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Novel biomarkers
Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;
Measured: 1YEARS
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start1 Jan 2026
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Why it stopped: Administrative withdrawal: This study was determined to be a continuation of \[NCT05718336\]. To avoid duplicate reporting and ensure consistent publication, this record is being consolidated into the prior study. No enrollment has occurred.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07565337
- Sponsor's protocol ID
- 202506174RINC
- Status last verified
- Apr 2026
- First submitted
- 7 Jan 2026
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT07565337
- Acronym / sponsor ID
- 202506174RINC
- Conditions
- Atrial Fibrillation, Biomarker
- Keywords
- biomarker, atrial fibrillation, AF burden, inflammation, fibrosis, heart failure
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Administrative withdrawal: This study was determined to be a continuation of \[NCT05718336\]. To avoid duplicate reporting and ensure consistent publication, this record is being consolidated into the prior study. No enrollment has occurred.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
Detailed description
With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring.
Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| afib | – | –From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study is a follow-up to the prospective generational study (AFTTER: Atrial Fibrillation Trial To Eliminate Risk-factors; NCT05718336) that enrolled patients from 2020 to 2023. After consenting to participate in this study, patients underwent a series of questionnaires, blood tests, and special examinations (see the figure below). The caregiver (the arrhythmia treatment team at National Taiwan University Hospital) formulated a treatment plan based on the examination results. After approximately two years (at least one year) of treatment, a post-test was conducted to conclude the study (a total of 343 patients were enrolled in this study, of which 266 participants completed the pre- and post-treatment tests and blood tests).
Key inclusion criteria (1 listed)
- -Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)
Key exclusion criteria (1 listed)
- -Subjects without complete pre- and post-treatment testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Novel biomarkers
Time frame: 1YEARS
Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation and Biomarker, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Novel biomarkers (time frame: 1YEARS). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.